Eli Lilly (NYSE: LLY) reported a blockbuster Q2 2026, with revenue of $22.97 billion, up 48% year-over-year, driven by record sales of Mounjaro ($9.9 billion) and Zepbound ($4.93 billion). The company also raised its FY2026 revenue guidance to $85–$87 billion, committed an additional $4.5 billion to expand U.S. manufacturing, advanced retatrutide toward an expected Q1 2027 FDA filing, progressed orforglipron for Type 2 diabetes, secured new approvals for Ebglyss and Jaypirca, and continued strengthening its pipeline through strategic acquisitions. Sector: Pharmaceuticals Key Highlights 💰 Q2 revenue: $22.97 billion, up 48% YoY 💉 Mounjaro generated $9.9 billion and Zepbound $4.93 billion in quarterly sales 🌍 U.S. revenue grew 33%, while international revenue surged 80% 📈 Raised FY2026 revenue guidance to $85–$87 billion 🏭 Committed an additional $4.5 billion to expand U.S. manufacturing 🧬 Advanced retatrutide toward a planned Q1 2027 FDA filing and progressed orforglipron for Type 2 diabetes ✅ Secured new approvals for Ebglyss and Jaypirca, while expanding its pipeline through strategic acquisitions Why It Matters Lilly's exceptional quarter highlights the continued strength of its obesity and diabetes franchise while demonstrating broad pipeline momentum, manufacturing expansion, and sustained global demand—reinforcing its leadership in next-generation therapeutics. Read More: https://www.thinksabio.com/reports/isr/LLY